JP2024512931A - 受容体相互作用タンパク質１阻害剤、その調製、及び使用 - Google Patents
受容体相互作用タンパク質１阻害剤、その調製、及び使用 Download PDFInfo
- Publication number
- JP2024512931A JP2024512931A JP2023556737A JP2023556737A JP2024512931A JP 2024512931 A JP2024512931 A JP 2024512931A JP 2023556737 A JP2023556737 A JP 2023556737A JP 2023556737 A JP2023556737 A JP 2023556737A JP 2024512931 A JP2024512931 A JP 2024512931A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- tautomer
- pharmaceutically acceptable
- alkyl
- membered heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021081514 | 2021-03-18 | ||
| CNPCT/CN2021/081514 | 2021-03-18 | ||
| PCT/CN2022/081544 WO2022194259A1 (en) | 2021-03-18 | 2022-03-17 | Receptor-interacting protein 1 inhibitors, preparations, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024512931A true JP2024512931A (ja) | 2024-03-21 |
| JP2024512931A5 JP2024512931A5 (https=) | 2025-03-25 |
Family
ID=83321909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023556737A Pending JP2024512931A (ja) | 2021-03-18 | 2022-03-17 | 受容体相互作用タンパク質１阻害剤、その調製、及び使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240217963A1 (https=) |
| EP (1) | EP4308555A4 (https=) |
| JP (1) | JP2024512931A (https=) |
| CN (1) | CN117500795A (https=) |
| CA (1) | CA3209628A1 (https=) |
| IL (1) | IL305530A (https=) |
| WO (1) | WO2022194259A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024233544A1 (en) | 2023-05-10 | 2024-11-14 | Genzyme Corporation | Isoxazolidines as ripk1 inhibitors and use thereof |
| CN121487930A (zh) | 2023-05-10 | 2026-02-06 | 建新公司 | 作为ripk1抑制剂的异噁唑烷及其用途 |
| CN121079291A (zh) | 2023-05-10 | 2025-12-05 | 建新公司 | 作为ripk1抑制剂的异噁唑烷及其使用 |
| CN120607513A (zh) * | 2024-03-08 | 2025-09-09 | 山东全重生物医药科技有限公司 | Ripk1抑制剂、其制备方法及其在医药上的应用 |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008005368A2 (en) * | 2006-06-30 | 2008-01-10 | Abbott Laboratories | Piperazines as p2x7 antagonists |
| JP2009528992A (ja) * | 2006-02-16 | 2009-08-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性エポキシド加水分解酵素阻害剤として有益な置換ピリジンアミン化合物 |
| JP2011510996A (ja) * | 2008-01-30 | 2011-04-07 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規ｓＥＨ阻害剤およびその使用 |
| WO2016101887A1 (en) * | 2014-12-24 | 2016-06-30 | National Institute Of Biological Sciences, Beijing | Necrosis inhibitors |
| WO2016185423A1 (en) * | 2015-05-19 | 2016-11-24 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| JP2018502101A (ja) * | 2014-12-24 | 2018-01-25 | ナショナル・インスティチュート・オブ・バイオロジカル・サイエンシズ，ベイジン | ネクローシス阻害薬 |
| JP2019535728A (ja) * | 2016-11-18 | 2019-12-12 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | キナーゼ阻害剤としての複素環式アミド |
| WO2020103859A1 (en) * | 2018-11-20 | 2020-05-28 | Sironax Ltd | RIP1 Inhibitors |
| WO2020103884A1 (en) * | 2018-11-20 | 2020-05-28 | Sironax Ltd | Cyclic Ureas |
| KR20200087922A (ko) * | 2019-01-11 | 2020-07-22 | 보로노이바이오 주식회사 | (3-페닐이속사졸리딘-2-일)(피페리딘-4-일)메타논 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200815426A (en) * | 2006-06-28 | 2008-04-01 | Astrazeneca Ab | New pyridine analogues II 333 |
| ES2404580T3 (es) * | 2007-10-11 | 2013-05-28 | Glaxosmithkline Llc | Novedosos inhibidores de la ehs y uso de los mismos |
| CA2813162C (en) * | 2010-10-20 | 2015-06-16 | Pfizer Inc. | Pyridine-2- derivatives as smoothened receptor modulators |
| HUE039922T2 (hu) * | 2012-12-11 | 2019-02-28 | Takeda Pharmaceuticals Co | Heterociklusos vegyületek |
-
2022
- 2022-03-17 CN CN202280022439.7A patent/CN117500795A/zh active Pending
- 2022-03-17 JP JP2023556737A patent/JP2024512931A/ja active Pending
- 2022-03-17 US US18/549,923 patent/US20240217963A1/en active Pending
- 2022-03-17 WO PCT/CN2022/081544 patent/WO2022194259A1/en not_active Ceased
- 2022-03-17 IL IL305530A patent/IL305530A/en unknown
- 2022-03-17 CA CA3209628A patent/CA3209628A1/en active Pending
- 2022-03-17 EP EP22770611.6A patent/EP4308555A4/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009528992A (ja) * | 2006-02-16 | 2009-08-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性エポキシド加水分解酵素阻害剤として有益な置換ピリジンアミン化合物 |
| WO2008005368A2 (en) * | 2006-06-30 | 2008-01-10 | Abbott Laboratories | Piperazines as p2x7 antagonists |
| JP2011510996A (ja) * | 2008-01-30 | 2011-04-07 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規ｓＥＨ阻害剤およびその使用 |
| WO2016101887A1 (en) * | 2014-12-24 | 2016-06-30 | National Institute Of Biological Sciences, Beijing | Necrosis inhibitors |
| JP2018502101A (ja) * | 2014-12-24 | 2018-01-25 | ナショナル・インスティチュート・オブ・バイオロジカル・サイエンシズ，ベイジン | ネクローシス阻害薬 |
| WO2016185423A1 (en) * | 2015-05-19 | 2016-11-24 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| JP2019535728A (ja) * | 2016-11-18 | 2019-12-12 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | キナーゼ阻害剤としての複素環式アミド |
| WO2020103859A1 (en) * | 2018-11-20 | 2020-05-28 | Sironax Ltd | RIP1 Inhibitors |
| WO2020103884A1 (en) * | 2018-11-20 | 2020-05-28 | Sironax Ltd | Cyclic Ureas |
| KR20200087922A (ko) * | 2019-01-11 | 2020-07-22 | 보로노이바이오 주식회사 | (3-페닐이속사졸리딘-2-일)(피페리딘-4-일)메타논 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 |
Non-Patent Citations (4)
| Title |
|---|
| HARRIS, PHILIP A.: ""Inhibitors of RIP1 kinase: a patent review (2016-present)"", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 31, no. 2, JPN6025051849, 4 December 2020 (2020-12-04), pages 137 - 151, ISSN: 0005765928 * |
| NI, XIAOMIN ET AL.: ""Structural Insights into Interaction Mechanisms of Alternative Piperazine-urea YEATS Domain Binder", ACS MEDICINAL CHEMISTRY LETTERS, vol. 10, no. 12, JPN6025051851, 25 November 2019 (2019-11-25), pages 1661 - 1666, ISSN: 0005765926 * |
| STN REGISTRY FILE, JPN7025005462, 27 May 2019 (2019-05-27), ISSN: 0005765927 * |
| ZHONG, WENHE ET AL.: ""Targeting the Bacterial Epitranscriptome for Antibiotic Development: Discovery of Novel tRNA-(N1G3", ACS INFECTIOUS DISEASES, vol. 5, no. 3, JPN6025051853, 25 January 2019 (2019-01-25), pages 326 - 335, ISSN: 0005765925 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20240217963A1 (en) | 2024-07-04 |
| IL305530A (en) | 2023-10-01 |
| CA3209628A1 (en) | 2022-09-22 |
| EP4308555A1 (en) | 2024-01-24 |
| CN117500795A (zh) | 2024-02-02 |
| WO2022194259A1 (en) | 2022-09-22 |
| EP4308555A4 (en) | 2025-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024512931A (ja) | 受容体相互作用タンパク質１阻害剤、その調製、及び使用 | |
| AU2013344049B2 (en) | ALK kinase inhibitors | |
| JP2022518860A (ja) | 免疫調節剤、組成物およびその使用方法 | |
| AU2007235577B2 (en) | Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor | |
| JP2020525522A (ja) | Ｒｈｏ−関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用 | |
| KR102680160B1 (ko) | 심부전의 치료를 위한 rock의 5원-아미노헤테로사이클 및 5,6- 또는 6,6-원 비시클릭 아미노헤테로시클릭 억제제 | |
| KR20240001709A (ko) | 화합물 및 cd38 억제제로서의 용도 | |
| EP1730119A1 (en) | Imidazole compounds for the treatment of neurodegenerative disorders | |
| NZ571691A (en) | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | |
| EP1869019A1 (en) | Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors | |
| EP4206197A1 (en) | Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method | |
| JP7604067B2 (ja) | ジアシルグリセロールキナーゼ阻害剤としての複素環化合物及びその用途 | |
| JP2025509846A (ja) | フェニルトリアゾールｍｌｌ１－ｗｄｒ５タンパク質－タンパク質間相互作用阻害剤 | |
| CA3206847A1 (en) | Modulators of fpr1 and methods of using the same | |
| CA3225785A1 (en) | Cd38 modulators and methods of use thereof | |
| IL300792A (en) | Compounds that inhibit ototaxin | |
| WO2022150316A1 (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer | |
| CA3202033A1 (en) | Selective inhibitors of rock1 and rock2 protein kinases and uses thereof | |
| CA3201152A1 (en) | Nitrogen containing 2,3-dihydroquinazolinone compounds as nav1.8 inhibitors | |
| EP3904348A1 (en) | Aminopyridine compound, preparation method therefor and use thereof | |
| CN116947846A (zh) | 一种并环衍生物及其制备方法和用途 | |
| CA3240077A1 (en) | Bcl-2 inhibitors | |
| HK40107958A (zh) | 受体相互作用蛋白1抑制剂、其制备及用途 | |
| EP0618204A1 (en) | Heterocyclic compound and cardiotonic containing the same as active ingredient | |
| KR20260022448A (ko) | 디히드로피리미딘-2,4(1h,3h)-디온을 함유하는 폴리시클릭 유도체 및 이의 약학적 조성물, 이의 제조 방법 및 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250314 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250314 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20251218 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260403 |